Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.

Lévi, F; Benavides, M; Chevelle, C; Le Saunier, F; Bailleul, F; Misset, J L; Regensberg, C; Vannetzel, J M; Reinberg, A; Mathé, G

Lévi, F; Benavides, M; Chevelle, C; Le Saunier, F; Bailleul, F; Misset, J L; Regensberg, C; Vannetzel, J M; Reinberg, A; Mathé, G.

Affiliation

Lévi F; Service des Maladies Sanguines, Immunitaires et Tumorales, Hôpital Paul-Brousse, Villejuif, France.

J Clin Oncol ; 8(4): 705-14, 1990 Apr.

Article in En | MEDLINE | ID: mdl-2179481

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Circadian Rhythm; Ovarian Neoplasms/drug therapy; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Cisplatin/administration & dosage; Doxorubicin/administration & dosage; Doxorubicin/analogs & derivatives; Drug Administration Schedule; Drug Evaluation; Female; Humans; Neoplasm Staging; Ovarian Neoplasms/mortality; Ovarian Neoplasms/pathology; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Circadian Rhythm Type of study: Clinical_trials Limits: Female / Humans Language: En Journal: J Clin Oncol Year: 1990 Type: Article Affiliation country: France

Search on Google

XML

PubMed Links